利用治疗药物保护前列腺癌患者骨骼健康
本综述回顾了前列腺癌骨病变形成的分子机制、预防SRE药物的作用方式及其在激素敏感或去势抵抗性前列腺癌中的疗效与安全性。地舒单抗和唑来膦酸被用于预防SRE,镭-223可延迟症状性SRE并改善总生存;低剂量地舒单抗可用于ADT相关骨丢失。临床应关注这些疗法的安全性。
要点
- 地舒单抗和唑来膦酸可用于预防前列腺癌患者的SRE。
- 镭-223能延迟症状性SRE并通过骨转移效应改善总生存。
- 低剂量地舒单抗可用于治疗ADT相关骨丢失。
核心结论
- 有令人信服的证据支持使用地舒单抗和双膦酸盐维持前列腺癌患者的骨骼健康。
- 临床医生应留意这些疗法的的不良事件风险特征。
研究设计与样本
- 综述文献,涵盖骨病变形成的分子机制、预防SRE药物的作用方式及其在激素敏感或去势抵抗性前列腺癌中的疗效与安全性。
主要发现
- 地舒单抗(RANKL抑制剂)和唑来膦酸(双膦酸盐)被用于预防SRE。
- 镭-223二氯化物在延迟症状性SRE及通过骨转移效应改善总生存方面具有确切疗效。
- 在骨转移发生前,低剂量地舒单抗可用于治疗ADT相关骨丢失。
- 地舒单抗可能具有延迟CRPC患者骨转移发展的潜力,但该适应症目前尚未获批。
临床怎么用
- 在前列腺癌临床病程中应考虑骨骼健康及预防SRE的疗法。
- 根据激素敏感或去势抵抗性疾病选择地舒单抗或双膦酸盐,并关注安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients are also at risk of bone loss due to androgen deprivation therapy (ADT), which can be compounded in elderly patients with reduced bone density. It is essential, therefore, that aspects of bone health and therapies able to prevent the occurrence of SREs are considered throughout the clinical course of prostate cancer. METHODS: We reviewed the literature regarding the molecular mechanisms underpinning bone lesion formation, the modes of action of therapies that prevent SREs, and the efficacy and safety of these therapies in patients with hormone-sensitive or castration-resistant prostate cancer (CRPC). RESULTS: Therapies such as denosumab (a RANKL inhibitor) and zoledronic acid (a bisphosphonate) were indicated for prevention of SREs. Radium-223 dichloride also has proven efficacy in delaying symptomatic SREs, as well as in improving overall survival through effects on bone metastases. Before development of bone metastases, low-dose denosumab may also be used for treatment of ADT-associated bone loss. Denosumab may also have the potential to delay bone metastases development in patients with CRPC, although this is not currently an approved indication. The safety profile of therapies to prevent SREs should be considered. This review consolidates the available evidence on use of denosumab and bisphosphonates in prostate cancer, differentiated by hormone-sensitive and castration-resistant disease. CONCLUSIONS: There is convincing evidence to support the use of denosumab and bisphosphonates to maintain bone health in patients with prostate cancer. Clinicians should be mindful of the adverse event risk profile of these therapies.
引用
- Miller K, Steger GG, Niepel D, et al. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 29988100. doi:10.1038/s41391-018-0060-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。